Anti-NFkB p105 / p50 (phospho S893) antibody (ab28850)


  • Product nameAnti-NFkB p105 / p50 (phospho S893) antibody
    See all NFkB p105 / p50 primary antibodies
  • Description
    Rabbit polyclonal to NFkB p105 / p50 (phospho S893)
  • Tested applicationsSuitable for: IHC-P, ELISA, WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthesized phosphopeptide derived from human NFKB p105/p50 around the phosphorylation site of Serine 893.

  • Positive control
    • IHC-P: breast carcinoma. WB: extracts from Hela cells.


Associated products


Our Abpromise guarantee covers the use of ab28850 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesELISA: 1/20000.
    IHC-P: 1/50 - 1/100.
    WB: 1/500 - 1/1000. Detects a band of approximately 100 kDa (predicted molecular weight: 106 kDa).

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionNF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.
    • Sequence similaritiesContains 7 ANK repeats.
      Contains 1 death domain.
      Contains 1 RHD (Rel-like) domain.
    • DomainThe C-terminus of p105 might be involved in cytoplasmic retention, inhibition of DNA-binding, and transcription activation.
      Glycine-rich region (GRR) appears to be a critical element in the generation of p50.
    • Post-translational
      While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
      Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.
      Polyubiquitination seems to allow p105 processing.
      S-nitrosylation of Cys-61 affects DNA binding.
    • Cellular localizationNucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor.
    • Information by UniProt
    • Database links
    • Alternative names
      • DKFZp686C01211 antibody
      • DNA binding factor KBF1 antibody
      • DNA binding factor KBF1 EBP1 antibody
      • DNA-binding factor KBF1 antibody
      • EBP 1 antibody
      • EBP-1 antibody
      • EBP1 antibody
      • KBF1 antibody
      • MGC54151 antibody
      • NF kappa B antibody
      • NF kappaB antibody
      • NF kappabeta antibody
      • NF kB1 antibody
      • NFkappaB antibody
      • NFKB 1 antibody
      • NFKB p105 antibody
      • NFKB p50 antibody
      • Nfkb1 antibody
      • NFKB1_HUMAN antibody
      • Nuclear factor kappa B DNA binding subunit antibody
      • Nuclear factor kappa-B, subunit 1 antibody
      • Nuclear factor NF kappa B p105 subunit antibody
      • Nuclear factor NF kappa B p50 subunit antibody
      • Nuclear factor NF-kappa-B p50 subunit antibody
      • Nuclear factor of kappa light chain gene enhancer in B cells 1 antibody
      • Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody
      • Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody
      • p105 antibody
      • p50 antibody
      • p84/NF-kappa-B1 p98 antibody
      • Transcription factor NFKB1 antibody
      see all

    Anti-NFkB p105 / p50 (phospho S893) antibody images

    • Ab28850, at a dilution of 1/50, staining p105 in paraffin embedded human breast carcinoma tissue by Immunohistochemistry.
      Left image: untreated.
      Right image: the same antibody preincubated with synthesized phosphopeptide.
    • All lanes : Anti-NFkB p105 / p50 (phospho S893) antibody (ab28850) at 1/500 dilution (using extracts from Hela cells (5-30ug).)

      Lane 1 : Using ab28850.
      Lane 2 : Using the same antibody preincubated with synthesized peptide.

      Predicted band size : 106 kDa
      Observed band size : 100 kDa (why is the actual band size different from the predicted?)

    References for Anti-NFkB p105 / p50 (phospho S893) antibody (ab28850)

    ab28850 has not yet been referenced specifically in any publications.

    Product Wall

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Sample Human Tissue sections (lung carcinoma)
    Specification lung carcinoma
    Fixative Formaldehyde
    Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citrate pH 6.0
    Permeabilization No
    Blocking step Serum as blocking agent for 10 minute(s) · Concentration: 1.5%

    Abcam user community

    Verified customer

    Submitted Sep 30 2008